Aditxt, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
Aditxt, Inc. (ADTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 60.00 thousand shares for the 1-month period ending 2021-02-24, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2023-11-14
- Aditxt, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2020 was 880.50K shares, a 25.79% increase from fiscal 2019.
- Aditxt, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2019 was 700.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 1 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month |
|---|---|---|---|
| 2021-02-24 | 60.00K shares 10-Q · filed 2023-11-14 | 3.00M shares 10-Q · filed 2021-05-12 | |
| 2020-12-31 | 880.50K shares 10-K · filed 2021-03-25 | ||
| 2019-12-31 | 700.00K shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |